MO39171 - Atezolizumab in locally advanced or metastatic NSCLC
Research type
Research Study
Full title
A Phase III/IV, single arm, mutlicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or metastatic non-small cell lung cancer (TAIL)
IRAS ID
231649
Contact name
Thomas Newsom-Davis
Contact email
Sponsor organisation
F Hoffmann-La Roche Ltd
Eudract number
2017-001409-34
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 9 months, 1 days
Research summary
Summary of Research
The purpose of this study is to compare the effect, good or bad, of atezolizumab, on non-small cell lung cancer.\n\nAtezolizumab is an antibody (a large, Y-shaped protein used by body’s immune system to identify and neutralise foreign objects such as bacteria, viruses and tumour cells) that affects the immune system by blocking the programmed death ligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in decreasing the body’s natural immune response to fight cancer. By blocking the pathway, atezolizumab may help the immune system stop or reverse the growth of tumours.
Summary of Results
Results submitted to clinicaltrials.gov on 15/03/2023 but not yet published.
https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbRehJ-2Fi4xyo44sEgJVCl5BcbW9wgc64X2JjNxW-2BqMpAM8brI4Dr5CbWuQPg8Hr4k5r-2BYQcfI8z-2BuBUDWvrER72xASL1H2jdXOFRkfEYWvcemzZed_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YJrb7XAbnID33Hpl2v3vapt58duSkuNMFA9ERoLVQb-2FIL7GnlfBHCy-2BCf62NBxW72a4phQ-2Fdh5el4uECMToSONikGn8SAPxao1sov3N6kjn1cOQ8g3a-2BAmR7T-2Bl0DOx-2FXsG5nxwBS4-2FWAtUqn8WkWWa6Uq-2FBUWj-2BnzothfBV9bhQtuSMPiKAPL7b1-2BHZ6QD5e8-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C6cbdd0aab3044de46ef808db35c1eaa3%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C638162879204971345%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=QWPkmdh6m7CDy3DJIOHDeLESogFW2I0RrvtGHXLrPwc%3D&reserved=0
REC name
South West - Central Bristol Research Ethics Committee
REC reference
17/SW/0279
Date of REC Opinion
19 Dec 2017
REC opinion
Further Information Favourable Opinion